INTERCEPT™ Blood System Presented at ISBT London

From June 27 to July 1, Cerus was present at the 25th Regional Congress of the International Society of Blood Transfusion (ISBT) ISBT in conjunction with the 33rd Annual Conference of the British Blood Transfusion Society, which took place at the London ExCel event centre.

The ISBT is an international network for transfusion medicine professionals from across the globe, who share knowledge to improve the safety of blood transfusion worldwide.

For the INTERCEPT™ Abstract Compilation from the 2015 ISBT International Congress, please click here.

On June 28, Cerus organised a round table discussion entitled: ‘What is the Future of Labile Plasma Products in European Blood Establishments?’

The introduction of pharmaceutical plasma preparations may impact the preparation of labile plasma components in blood services. This raises a number of questions:

  • How do these pharmaceutical plasma preparations compare clinically and economically with the different labile plasma components prepared in blood centres?
  • What are the implications for blood centres if hospital customers shift to pharmaceutical plasma preparations?
  • Does the increasing clinical need for a variety of labile plasma components offer new opportunities for blood services to create added value for their hospital customers?

If you’d like to receive the slides for this presentation, please contact us at contact@cerus.com. 

On June 29, Cerus presented a workshop titled: ‘Forward Momentum in Providing Safer Blood Components – New Pathogen Inactivation Developments for Platelets, Plasma, and Red Cells’. The workshop highlighted the need for pathogen inactivation in providing safe blood components, and detailed the recent progress made to meet this need.

Source: International Society of Blood Transfusion